•
Sep 30, 2021
Nuvation Bio Q3 2021 Earnings Report
Reported a net loss, progress in clinical trials, and pipeline expansion.
Key Takeaways
Nuvation Bio reported a net loss for Q3 2021, but highlighted progress in clinical trials for NUV-422 and NUV-868, as well as expansion of their pipeline with new drug candidates.
Reported a net loss of $53.1 million for the third quarter of 2021.
Advanced clinical trials for NUV-422 in HRD+ cancers and NUV-868 in lung cancer.
Expanded pipeline with the addition of new drug candidates targeting unmet medical needs.
Continued to strengthen the balance sheet to support ongoing research and development activities.